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Abstract
Background: Higher ultrafiltration (UF) rates and extracellular hypo- and hypervolemia are associated with adverse
outcomes among maintenance hemodialysis patients. The Centers for Medicare and Medicaid Services recently
considered UF rate and target weight achievement measures for ESRD Quality Incentive Program inclusion. The
dual measures were intended to promote balance between too aggressive and too conservative fluid removal. The
National Quality Forum endorsed the UF rate measure but not the target weight measure. We examined the
proposed target weight measure and quantified weight gains if UF rate thresholds were applied without treatment
time (TT) extension or interdialytic weight gain (IDWG) reduction.
Methods: Data were taken from the 2012 database of a large dialysis organization. Analyses considered 152,196
United States hemodialysis patients. We described monthly patient and dialysis facility target weight achievement
patterns and examined differences in patient characteristics across target weight achievement status and
differences in facilities across target weight measure scores. We computed the cumulative, theoretical 1-month
fluid-related weight gain that would occur if UF rates were capped at 13 mL/h/kg without concurrent TT extension
or IDWG reduction.
Results: Target weight achievement patterns were stable over the year. Patients who did not achieve target weight
(post-dialysis weight ≥ 1 kg above or below target weight) tended to be younger, black and dialyze via catheter, and
had shorter dialysis vintage, greater body weight, higher UF rate and more missed treatments compared with patients
who achieved target weight. Facilities had, on average, 27.1 ± 9.7% of patients with average post-dialysis weight ≥ 1 kg
above or below the prescribed target weight. In adjusted analyses, facilities located in the midwest and south and
facilities with higher proportions of black and Hispanic patients and higher proportions of patients with shorter TTs were
more likely to have unfavorable facility target weight measure scores. Without TT extension or IDWG reduction, UF rate
threshold (13 mL/h/kg) implementation led to an average theoretical 1-month, fluid-related weight gain of 1.4 ± 3.0 kg.
Conclusions: Target weight achievement patterns vary across clinical subgroups. Implementation of a maximum UF
rate threshold without adequate attention to extracellular volume status may lead to fluid-related weight gain.
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Background
Adequate fluid management is increasingly accepted as
an important component of hemodialysis treatment ad-
equacy. Existing data suggest that rapid fluid removal,
extracellular volume expansion and large interdialytic
weight gain (IDWG) are risk factors for morbidity and
mortality among maintenance hemodialysis patients
[1–6]. Growing interest in evaluating the quality of dia-
lysis facility fluid management practices led to the re-
cent consideration of two fluid-related clinical quality
measures, an ultrafiltration (UF) rate measure and a
target weight measure, for inclusion in the United
States (U.S.) Centers for Medicare and Medicaid
Services (CMS) End-Stage Renal Disease (ESRD)
Quality Incentive Program (QIP) [7].
The ESRD QIP is the first mandatory, federal pay-
for-performance program in the U.S. The program
links Medicare payment for dialysis services to dialy-
sis facility performance on quality measures. The
current QIP includes quality measures on dialysis ad-
equacy, anemia, mineral metabolism, and vascular ac-
cess, among others. Measure development relies on
Technical Expert Panels, public comment and meas-
ure endorsement by the National Quality Forum
(NQF). Measures may be developed by CMS as well
as by other stakeholder groups [8]. The UF rate and
target weight measures were proposed as companion
measures by a dialysis stakeholder coalition. The dual
measures were intended to promote balance between
too aggressive fluid removal and too conservative
fluid removal [9]. In 2015, the NQF endorsed only
the UF rate measure (now slated for QIP inclusion in
payment year 2020), declining to recommend the tar-
get weight measure based on inadequate evidence and
other concerns [7].
To reduce UF rates, providers can extend treatment
times (TTs) or lower UF volumes. Patient preferences
and facility operational burden may limit TT extension
[10, 11]. To reduce UF volume without consequent vol-
ume expansion, IDWGs must be reduced. However,
minimizing IDWG is difficult. If UF rate thresholds are
adopted without adequate attention to extracellular vol-
ume status, patients may not achieve target weight and
become volume-expanded over time. Mismatch between
post-dialysis and target weights may occur for numerous
reasons. Inaccurate target weight estimation may result
in post-dialysis weights either above or below target
weight. Intradialytic UF reduction or cessation with or
without fluid bolus administration may lead to post-
dialysis weights above target weights. Difficulties with
target weight achievement should prompt clinical pro-
viders to reconsider either their approach to fluid re-
moval or the target weight prescription. However, target
weight adjustment is often overlooked. While target
Table 1 Kidney Care Quality Alliance (KCQA) target weight measure specifications and selection criteriaa
Target Weight Measure
Description % of patients in the facility with an average post-dialysis weight ≥ 1 kg
above or below the prescribed target weight
Time window 12 months
Calculation period Week of the monthly Kt/V
Numeratora Number of patients in the facility with an average post-dialysis weight ≥ 1 kg
above or below the prescribed target weight during the calculation period
Denominator Total number of adult in-center HD patients at the reporting facility meeting inclusion criteria
Exclusions 1) PD or home HD patients;
2) Age < 18 years;
3) Treatment without post-weight and target weight;
4) Patient present at reporting facility < 30 days;
5) Patient at facility with < 11 patients during month;
6) < 7 HD treatments at the facility in the reporting month
Algorithm Calculated on a monthly basis and then averaged over year:
1) Sum denominator patients for each facility month
2) Sum numerator patients for each facility month
3) Calculate monthly score = numerator patients / denominator patients for each month
4) Calculate annual score = (sum of monthly scores) / # of months in reporting year
Score type Rate / proportion
Score interpretation Lower score more favorable
aThe monthly target weight measure was calculated by dividing the total number of facility patients with an average post-dialysis weight ≥ 1 kg above or below target
weight by the total number of facility hemodialysis patients meeting measure selection criteria on a monthly basis. For patients meeting the denominator selection
criteria in the reporting month, the difference between the post-dialysis weight and the prescribed target weight for each treatment in the calculation period (during
the week of the Kt/V assessment) was calculated. An average post-dialysis and prescribed target weight difference was then calculated from the treatments during the
Kt/V assessment week. The number of patients in each facility with an average post-weight and target weight difference that was ± ≥ 1 kg during the calculation period
were considered in the measure numerator. The annual target weight measure score was calculated by averaging facility monthly scores
Abbreviations: HD Hemodialysis, PD Peritoneal dialysis
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weight estimation is imperfect, target weight achieve-
ment has been associated with improved clinical out-
comes [12, 13]. Target weight achievement is thus a
plausible indicator of facility extracellular fluid manage-
ment practices and a potential counterbalance for the
UF rate quality measure.
We undertook this study to assess the proposed target
weight quality measure by describing target weight
achievement patterns across individuals and comparing
dialysis facilities with higher (vs. lower) percentages of
patients with failed target weight achievement. Also, we
examine the associations of facility characteristics with
higher (vs. lower) percentages of patients with failed tar-
get weight achievement, and calculate the theoretical
amount of fluid-related weight that would be gained if
an UF rate threshold of 13 mL/h/kg was implemented
without concurrent IDWG reduction or TT extension.
Methods
Target weight achievement measure
We evaluated the Kidney Care Quality Alliance
(KCQA)-proposed post-dialysis weight above or below
target weight measure (Measure 2702) submitted to
the May 2015 NQF. The measure was submitted as a
companion measure to the KCQA-proposed UF rate
measure (Measure 2701) [7]. The KCQA is a measure
development committee sponsored by Kidney Care
Partners, an alliance of dialysis stakeholders including
patients, professionals, providers and manufacturers
that aims to optimize kidney disease care through le-
gislative, regulatory and quality activities [14].
Using 2012 data from a single dialysis organization, we
analyzed the post-dialysis weight above or below target
weight measure (henceforth referred to as the “target
weight measure”) according to KCQA measure specifica-
tion at the patient and facility levels (Table 1; Additional
file 1: Table S1) [15]. The target weight measure reflects
the percentage of patients at a dialysis facility with aver-
age post-dialysis weights ≥1 kg above or below
prescribed target weight. The ±1 kg target weight differ-
ence was the difference magnitude proposed by measure
developers. The measure is reported as a proportion
(percentage of facility patients with average post-dialysis
weights ≥1 kg above or below prescribed target weight).
A lower score is better.
The target weight measure was calculated by dividing
the total number of facility patients with an average
post-dialysis weight ≥ 1 kg above or below target weight
by the total number of facility patients meeting meas-
ure selection criteria on a monthly basis. Per measure
developer specifications, the monthly measure was
computed as a mean of post-dialysis and target weight
differences from treatments during the week of the
monthly Kt/V assessment. Facility monthly measure
percentages were averaged to create an annual facility
measure score. Annual scores were dichotomized at the
75th percentile consistent with CMS facility perform-
ance measure evaluation.
Primary analyses considered the target weight
measure as specified by KCQA. Secondary analyses
considered a binary measure specification: patients
with post-dialysis weight ≥ 1 kg above target weight
were considered separately from patients with post-
dialysis weight ≥ 1 kg below target weight. Add-
itional secondary analyses considered facility target
weight measure scores in conjunction with UF rate
measure scores. The UF rate measure reflects the
percentage of facility patients with average delivered
Fig. 1 Flow diagram of the unique target weight measure cohort
based on application of measure selection criteria on a rolling
monthly basis. Abbreviations: LDO, large dialysis organization; HD,
hemodialysis; PD, peritoneal dialysis
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UF rates ≥13 mL/h/kg and average delivered TTs
<240 min. Measure specifics have been reported
previously [11].
Study design and selection criteria
This study was approved by the University of North
Carolina at Chapel Hill Institutional Review Board.
Data were taken from the records of 196,635 patients
from 2449 U.S. facilities in the 2012 electronic med-
ical record of a single dialysis provider. Cohort entry
occurred between January 1 and November 30, 2012
and was based on rolling monthly application of se-
lection criteria. Patients entered and exited the
cohort throughout the year and could contribute to
different facility monthly cohorts. This design mirrors
real-world measure implementation and facilitated
calculation of monthly and annual proportions of fa-
cility patients with post-dialysis weigh-arget weight
differences outside of the proposed 1 kg threshold. Pa-
tient and facility eligibility criteria were assessed
monthly and were based on the selection criteria set-
forth by the measure developers. In-center hemodialysis
patients aged ≥18 years who were present at the report-
ing facility for ≥30 days were included. Peritoneal dialy-
sis and home hemodialysis patients, patients dialyzing
at facilities with <11 patients, patients with incomplete
Table 2 Patient characteristics by target weight achievement group as of the first reporting month in 2012a
Characteristic Achieved target weightb
(n = 104,377)
Missed target weightc
(n = 47,819)
Below target weightd
(n = 17,466)
Above target weighte
(n = 30,353)
Post-dialysis weight and target weight difference
Mean ± SD 0.0 ± 0.5; 0.6 ± 3.3; −2.7 ± 2.4; 2.5 ± 1.9;
Median [Q1, Q3] 0.0 [−0.3, 0.4] 1.3 [−1.5, 2.2] −1.9 [−3.2, −1.3] 1.9 [1.4, 2.9]
Age (years) 62.9 ± 15.0 61.0 ± 14.9 62.5 ± 15.0 60.2 ± 14.8
Female sex 46,842 (44.9) 21,604 (45.2) 8100 (46.4) 13,504 (44.5)
Black race 37,129 (35.6) 18,210 (38.1) 6399 (36.6) 11,811 (38.9)
Hispanic ethnicity 18,268 (17.5) 8079 (16.9) 3039 (17.4) 5040 (16.6)
Time on dialysis
< 1 years 33,105 (31.7) 16,770 (35.1) 7904 (45.3) 8866 (29.2)
1–5 years 45,341 (43.4) 20,371 (42.6) 6216 (35.6) 14,155 (46.6)
> 5 years 25,931 (24.8) 10,678 (22.3) 3346 (19.2) 7332 (24.2)
Access type
Graft 18,840 (18.1) 8222 (17.2) 2675 (15.4) 5547 (18.3)
Fistula 58,615 (56.2) 23,714 (49.7) 7417 (42.6) 16,297 (53.8)
Catheter 26,764 (25.7) 15,781 (33.1) 7330 (42.1) 8451 (27.9)
Pre-dialysis SBP
< 100 mmHg 1202 (1.2) 832 (1.7) 347 (2.0) 485 (1.6)
100–129 mmHg 19,979 (19.1) 10,036 (21.0) 4000 (22.9) 6036 (19.9)
130–159 mmHg 50,801 (48.7) 21,782 (45.6) 8009 (45.9) 13,773 (45.4)
≥ 160 mmHg 32,388 (31.0) 15,163 (31.7) 5108 (29.2) 10,055 (33.1)
History of heart failure 25,204 (24.1) 12,679 (26.5) 3417 (19.6) 9262 (30.5)
History of diabetes 42,687 (40.9) 20,335 (42.5) 6144 (35.2) 14,191 (46.8)
Post-dialysis weight (kg) 78.7 ± 21.5 83.9 ± 25.0 80.0 ± 23.5 86.2 ± 25.6
Prescribed TT <240 min 74,970 (71.8) 31,982 (66.9) 12,157 (69.6) 19,825 (65.3)
UF volume (L) 2.4 ± 1.2 2.7 ± 1.7 2.3 ± 1.8 2.9 ± 1.5
Prescribed UF rate (mL/h/kg) 8.6 ± 4.5 9.3 ± 5.6 7.7 ± 6.0 10.2 ± 5.2
Missed treatments ≥3 11,307 (10.8) 7921 (16.6) 3686 (21.1) 4235 (14.0)
eKt/V 1.7 ± 0.3 1.6 ± 0.3 1.6 ± 0.3 1.6 ± 0.3
aPatient N = 152,196. Values presented as means ± SDs, medians [quartile 1, quartile 3] or numbers (percentages). Because patients entered and exited the cohort
according to selection criteria application on a rolling monthly basis, the first reporting month varied across patients
bAverage post-dialysis weight < 1 kg above or below the prescribed target weight
cAverage post-dialysis weight ≥ 1 kg above or below the prescribed target weight
dAverage post-dialysis weight ≥ 1 kg below the prescribed target weight (below depicted by a negative sign)
eAverage post-dialysis weight ≥ 1 kg above the prescribed target weight
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post-dialysis weight or target weight data and patients
with <7 treatments at the facility in the reporting
month were excluded. These selection criteria were
proposed by the measure developers to promote equit-
able assessment of target weight achievement across fa-
cilities and to focus on patients within facility control
during the assessment period (i.e. to avoid undue influ-
ence from patients with prolonged hospitalizations or
high percentages of missed outpatient treatments).
In analyses estimating theoretical fluid-related
weight gain after application of an UF rate threshold
of 13 mL/h/kg, we considered patients with complete
treatment data from February 2012 (i.e. no missed
outpatient treatments and no missing pre-weight,
post-weight or target weight data) and who survived
60 days after the end of February 2012. In these ana-
lyses, IDWG was calculated as: pre-dialysis weight
minus post-dialysis weight from prior treatment. Pre-
scribed UF rate (mL/h/kg) was calculated as: IDWG
(mL)/ prescribed TT (h)/ post-dialysis weight (kg).
Data collection
Study data were taken from the dialysis provider’s elec-
tronic medical record. Demographic and co-morbid
data were documented at the time of admission to the
dialysis organization and updated based on clinical
course. Clearance (Kt/V) was measured at least
monthly per standard protocols. When more than one
monthly Kt/V was available, the last monthly value
was used. Dialysis variables including pre- and post-
dialysis weights, target weight and TTs were recorded
each treatment. Zip codes were used for facility geo-
graphic region assignment.
Statistical analyses
Analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC). Patient and facility characteris-
tics were described as numbers (percentages) for cat-
egorical variables and means ± standard deviations or
medians [quartile 1, quartile 3] for continuous vari-
ables. Target weight achievement (vs. not) was sum-
marized across the full cohort. Differences in facility
characteristics across annual target weight facility
measure scores (≤75th percentile vs. >75th percent-
ile) were assessed by Chi-square tests for categorical
variables and Student’s T-test for continuous vari-
ables. Adjusted associations between facility charac-
teristics and annual facility target weight measure
Table 3 Facility characteristics by annual facility target weight measure scorea
Target Weight Measureb
Characteristic ≤75th measure percentile
(n = 1406)
>75th measure percentile
(n = 468)
pc
Geographic region
Northeast 139 (9.9) 56 (11.9) ≤0.01
Midwest 361 (25.7) 90 (19.2)
South 659 (46.9) 195 (41.6)
West 246 (17.5) 128 (27.3)
Monthly facility size (number of patients) 59.7 ± 36.9 63.8 ± 40.0 <0.05
Household income ($)d 52,251 ± 20,018 50,489 ± 19,735 NS
Age < 50 years 18.2 ± 8.0 20.3 ± 7.9 <0.01
Black race 33.8 ± 29.7 40.6 ± 32.8 <0.01
Black race >50% of facility patients 412 (29.3) 182 (38.8) <0.01
Hispanic ethnicity 13.0 ± 19.8 16.2 ± 22.8 <0.01
Hispanic ethnicity >25% of facility patients 241 (17.2) 111 (23.7) <0.01
Heart failure balance >25% of facility patients 808 (57.5) 254 (54.2) NS
Prescribed TT <240 min 70.9 ± 19.0 73.7 ± 17.6 <0.01
Prescribed TT <240 min >50% of facility patients 1190 (84.7) 422 (90.0) <0.01
Prescribed UF rate ≥ 13 mL/h/kg 18.9 ± 10.1 20.3 ± 9.8 <0.01
Prescribed UF rate ≥ 13 mL/h/kg >33% of facility patients 121 (8.6) 51 (10.9) NS
aFacility N = 1874. Values presented as numbers (percentages) of facilities or means ± SDs of the percentage of facility patients. Using prescribed TT as an
example, a mean of 70.9% of patients at facilities in the ≤75th measure percentile had a prescribed TT <240 min as compared to a mean of 73.7% of patients at
facilities in the >75th measure percentile
bThe 75th percentile represents 32.9% of facility patients with post-dialysis weight ≥ 1 kg above or below the prescribed target weight. Measure 75th percentile
reflects the 75th percentile of the annual measure score, and facility data reflect the January 2012 cohort data
cSignificance was assessed by Chi-square test for categorical variables and Student’s T-test for continuous variables
dMean of the median household incomes. Income data was obtained from 2010 U.S. Census data based upon dialysis facility zip code
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scores were determined using multivariable logistic
regression models. The outcome of interest was the
facility annual target weight measure score (≤75th vs.
>75th percentile). Two-tailed P values <0.05 indicated
statistical significance.
To demonstrate potential theoretical fluid-related
weight gain resulting from implementation of an UF
rate threshold of 13 mL/h/kg without concurrent
IDWG reduction or TT extension, we calculated fluid-
related weight gains using observed IDWGs and pre-
scribed TTs during consecutive treatments in a single
month. For each treatment, we computed the max-
imum UF volume (L) allowable under the constraint of
a maximum prescribed UF rate of 13 mL/h/kg using
the patient’s prescribed TT and post-dialysis weight
from the previous treatment. The theoretical per treat-
ment weight change (kg) was calculated as: actual
IDWG minus maximum allowable UF. Cumulative
fluid-related weight change was then calculated by
summing weight changes across the study month of
interest. Detailed methods are provided in Additional
file 1: Table S2.
Results
Cohort characteristics and target weight measure description
Target weight measure analyses considered 152,196
unique patients from 1874 facilities (Fig. 1). The mean
age was 61 years, 36.4% were black, 17.3% were His-
panic, 24.9% had heart failure and 70.3% had prescribed
TTs <240 min in the first reporting month of 2012. The
cohort was similar to the broader U.S. hemodialysis
population in terms of age, race, heart failure status and
prescribed dialysis TT [16]. On average, target weight
prescriptions were changed 0.55 ± 0.80 times per
month.
The annual patient-level mean post-dialysis-target
weight difference was 0.3 ± 1.2 kg. Monthly patient-level
mean post-dialysis-target weight differences were stable
Table 4 Facility characteristics by annual facility ultrafiltration rate and target weight measure scoresa
Ultrafiltration Rate Measure and Target Weight Measureb
Characteristic ≤75th percentile for both measures
(n = 1062)
>75th percentile for one but not both measures
(n = 682)
>75th percentile for both measures
(n = 130)
Geographic region
Northeast 115 (10.8) 75 (11.0) 5 (3.8)
Midwest 267 (25.1) 157 (23.0) 27 (20.8)
South 521 (49.1) 286 (41.9) 47 (36.2)
West 159 (15.0) 164 (24.0) 51 (39.2)
Monthly facility size
(number of patients)
58.6 ± 35.9 62.6 ± 39.5 68.2 ± 41.4
Household income ($)c 51,870 ± 20,062 52,300 ± 19,911 48,750 ± 19,211
Age < 50 years 18.1 ± 8.1 19.0 ± 8.0 21.5 ± 7.2
Black race 35.1 ± 30.4 36.3 ± 30.9 34.0 ± 31.4
Black race >50% of
facility patients
337 (31.7) 219 (32.1) 38 (29.2)
Hispanic ethnicity 12.1 ± 19.1 14.8 ± 21.0 22.8 ± 26.8
Hispanic ethnicity >25%
of facility patients
163 (15.3) 143 (21.0) 46 (35.4)
Heart failure balance
>25% of facility patients
603 (56.8) 383 (56.2) 76 (58.5)
Prescribed TT <240 min 67.1 ± 19.6 76.5 ± 16.2 83.0 ± 10.7
Prescribed TT <240 min
>50% of facility patients
849 (79.9) 633 (92.8) 130 (100.0)
Prescribed UF
rate ≥ 13 mL/h/kg
15.4 ± 7.5 23.2 ± 10.6 30.4 ± 8.5
Prescribed UF
rate ≥ 13 mL/h/kg
>33% of facility patients
19 (1.8) 107 (15.7) 46 (35.4)
aFacility N = 1874. Values presented as numbers (percentages) of facilities or means ± SDs of the percentage of facility patients
bThe 75th percentile of the target weight measure represents 32.9% of facility patients with post-dialysis weight ≥ 1 kg above or below the prescribed target
weight. The 75th percentile of the ultrafiltration rate measure represents 20.3% of facility patients with UF rate ≥ 13 mL/h/kg and prescribed TT <240 min.
Measure 75th percentile reflects the 75th percentile of the annual measure score, and facility data reflect the January 2012 cohort data
cMean of the median household incomes. Income data was obtained from 2010 U.S. Census data based upon dialysis facility zip code
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over the year (Additional file 1: Table S3). Facilities had,
on average, 27.1 ± 9.7% of patients with average post-
dialysis weight ≥ 1 kg above or below the prescribed tar-
get weight. Monthly facility target weight measure scores
varied over the year with scores peaking in winter
(29.0 ± 11.9%) and nadiring in summer (25.7 ± 11.0%)
(Additional file 1: Figure S1 and Table S3). Secondary
analyses considering monthly post-dialysis-target weight
differences specified as ≥1 kg below vs. ≥1 kg above
target weight are displayed in Additional file 1: Table S4.
Patient and facility characteristics across target weight
achievement groups
Patients who did not achieve target weight (post-dialysis
weight ≥ 1 kg above or below target weight) tended to
be younger, black and dialyze via catheter, and had
shorter dialysis vintage, greater body weight, higher UF
rate and more missed treatments compared with pa-
tients who achieved target weight. When patients who
missed target weight were dichotomized by above or
below missed target weight status, patients with mean
post-dialysis weights ≥1 kg above target weight were
more likely to be younger, have histories of heart failure
and diabetes, longer dialysis vintage, greater body
weight, UF volume and UF rate and fewer missed treat-
ments, compared to patients with mean post-dialysis
weights ≥1 kg below target weight (Table 2).
Facilities in the highest measure quartile (>32.9% of
patients with average post-dialysis weights ≥1 kg above
or below the prescribed target weight), indicating worse
performance, were more likely to be located in the west-
ern U.S., treat a greater number of patients, and have
more black and Hispanic patients and more patients
with TTs <240 min and UF rates ≥13 mL/h/kg (Table 3).
Facilities in the highest measure quartile had signifi-
cantly fewer target weight prescription changes per
month compared to facilities in the lower target weight
measure quartiles (0.39 ± 0.65 vs. 0.60 ± 0.84;
p = 0.005). In secondary analyses, facilities falling in the
highest target weight measure quartile and the highest
UF rate measure quartile (>32.9% of patients with aver-
age post-dialysis weights ≥1 kg above or below the target
weight and >20.3% of patients with average UF rates
≥13 mL/h/kg and average TTs <240 min) were more
likely to be located in the western U.S., treat more
patients and have more Hispanic patients (Table 4).
In adjusted analyses, dialysis facilities located in the
midwest and south (vs. west), and facilities with higher
proportions of black and Hispanic patients and higher
Table 5 Adjusted associations between facility characteristics and less favorable facility target weight measure score (>75th percentile)a,b
Characteristic Adjusted OR (95% CI)
Geographic region
West 1.00 (reference)
Midwest 2.33 (1.61–3.37)
South 2.68 (1.91–3.77)
Northeast 1.34 (0.88–2.02)
Monthly facility size (number of patients)
≤ 25 1.93 (0.81–4.56)
26–50 1.86 (0.91–3.77)
51–100 1.51 (0.91–3.80)
≥ 101 1.00 (reference)
Household income > median zip code income ($)c 1.20 (0.96–1.50)
Age (per 10 years) 1.00 (1.00–1.01)
Black race >50% of facility patients 2.34 (1.78–3.07)
Hispanic ethnicity >25% of facility patients 1.45 (1.06–1.99)
Heart failure balance >25% of facility patients 0.79 (0.63–1.00)
Prescribed TT <240 min in >50% of facility patients 1.62 (1.15–2.28)
Prescribed UF rate ≥ 13 mL/h/kg in >33% of facility patients 1.31 (0.91–1.88)
aFacility N = 1874. The multivariable binary logistic regression model with a dependent outcome of annual target weight measure score ≤ 75th percentile vs.
>75th percentile was adjusted for geographic region (midwest, south, northeast vs. west), unit size (≤25, 26–50, 51–100 vs. ≥101 patients), household income
(≤ vs. > median zip code income), age (per 10 years), black race (≤50% vs. >50% of facility patients), Hispanic ethnicity (≤25% vs. >25% of facility patients),
heart failure balance (≤25% vs. >25% of facility patients), prescribed TT <240 min (≤50% vs. >50% of facility patients), and prescribed UF rate ≥ 13 mL/h/kg
(≤33% vs. >33% of facility patients)
bThe 75th percentile represents 32.9% of facility patients with post-dialysis weight ≥ 1 kg above or below the prescribed target weight. Measure 75th percentile
reflects the 75th percentile of the annual measure score, and facility data reflect the January 2012 cohort data
c Mean of the median household incomes. Income data was obtained from 2010 U.S. Census data based upon dialysis facility zip code
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proportions of individuals with TTs < 240 min were
more likely to have unfavorable (i.e. higher) facility
target weight measure scores (Table 5).
Individual fluid-related weight gains in the setting of
Ultrafiltration rate thresholds
Among 59,953 patients in the fluid-related weight gain
calculation cohort (Fig. 2), 11,161 (18.6%) had average
post-dialysis weights ≥1 kg above or below the pre-
scribed target weight in February 2012. Fig. 3 depicts a
single patient’s 1-month weight gain in response to ap-
plication of an UF rate threshold of 13 mL/h/kg with no
change in observed IDWGs and prescribed TTs. Overall,
the mean 30-day cumulative weight difference was
1.4 ± 3.0 kg. Patients with heart failure, shorter TT,
greater IDWG and higher UF rates had greater cumula-
tive weight gains (Table 6). When weight gains were
considered at the facility level, on average, 17.4 ± 10.8%
of facility patients had 30-day weight gains ≥2 kg,
13.3 ± 9.6% had 30-day weight gains ≥3 kg and
10.6 ± 8.5% had 30-day weight gains ≥4 kg. Higher facil-
ity percentages at each fluid-related weight gain level
were observed among females, patients with heart fail-
ure, shorter TTs, greater IDWGs and higher UF rates
(Table 7).
Discussion
In this study we examined target weight achievement
patterns, the proposed but unendorsed target weight
clinical performance measure and estimated the theoret-
ical cumulative fluid-related weight gains that could
result from UF rate threshold implementation. Patient-
level target weight achievement patterns remained gen-
erally stable over the year, but facility target weight
measure scores fluctuated, with the highest percentage
of facility patients missing target weight in winter.
Patients who did not achieve target weight were more
likely to be younger, black, heavier, dialyze via catheter,
have higher UF rates and more missed treatments com-
pared to patients who achieved target weight. Facilities
with higher percentages of patients who did not achieve
target weight were more likely to be located in the west-
ern U.S., treat more patients and have more black and
Hispanic patients compared with facilities with lower
percentages. Without concurrent TT extension or
IDWG reduction, implementation of an UF rate thresh-
old of 13 mL/h/kg led to a mean theoretical fluid-related
weight gain of 1.4 ± 3.0 kg with greater gains among fe-
males and patients with heart failure, shorter TTs and
greater IDWGs.
Among maintenance hemodialysis patients, overly
rapid fluid removal can lead to end-organ ischemic in-
jury and associated morbidity [5, 17]. Alternatively,
insufficient fluid removal can lead to volume overload
and associated adverse outcomes [3, 4]. In practice, clini-
cians seek to balance the ischemic consequences of
overly aggressive UF with the volume overload conse-
quences of overly conservative UF. To lower UF rates,
providers can increase TTs or lower UF volumes. In gen-
eral, patients are averse to longer TTs [10], and a recent
analysis demonstrated substantial facility operational
burden (clinic resources, staff time, disruption of patient
and transportation schedules) from extended treatments
[11]. Furthermore, IDWGs remain high despite inclusion
of salt and fluid restriction education in dietary pro-
grams [18]. These realities raise legitimate concern that
UF rate reduction may be challenging in some settings.
Thus, when extracellular volume status is not adequately
emphasized, UF rate threshold implementation may lead
to fluid-related weight gain. Target weight achievement
assessment is one potential approach to balancing po-
tential unintended consequences from UF rate
limitation.
Clinical quality measures are tools to measure and
track health care service quality. The Agency for Health-
care and Research Quality cites importance, scientific
Fig. 2 Flow diagram of the restricted cohort for fluid-related weight gain
analyses. a To calculate the IDWG at the first February hemodialysis
treatment, we required the post-dialysis weight from the last treatment
in January and hence required patients to receive treatment at the same
facility in January and February. Abbreviations: HD, hemodialysis; IDWG,
interdialytic weight gain
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soundness and feasibility as desirable attributes. Mea-
sures should also have the capacity to be stratified by
subgroups to evaluate for care disparities across popula-
tions [19]. Our data highlight differences among patients
(and facilities) who achieve target weight (vs. not). We
reported that, compared to patients who achieved target
weight, patients who did not achieve target weight were
younger, more likely to be black and had greater body
weights, among other differences. Facilities with greater
proportions of patients who did not achieve target
weight were more likely be located in the western U.S.,
treat more patients and have more black and Hispanic
patients compared with facilities with lower percentages.
These differences suggest that facility case-mix adjust-
ments to target weight measure scores may be needed.
The importance of an extracellular volume status
measure as a counter-balance to an UF rate measure
should not be underestimated, particularly in the U.S.
where TTs are notably shorter than elsewhere in the
world [20]. In previous analyses, we demonstrated that
facilities treating >100 patients would require, on aver-
age, 33 additional treatment hours per week to lower
UF rates to 13 mL/h/kg without concurrent IDWG re-
duction [11]. Such TT extension has implications for
staffing, facility costs and, most importantly, other pa-
tients’ treatment schedules. If facilities are not able to
meet these operational demands or if patients decline
TT extension and IDWGs are not sufficiently lowered,
fluid-related weight gain will occur in response to UF
rate reduction. In this study we demonstrated that, on
average, patients would gain 1.4 ± 3.0 kg under this
paradigm. Weight gains were higher among non-blacks
and patients with heart failure, and shorter treatment
times. When considered at the facility level, on aver-
age, 17% of facility patients gained ≥2 kg, 13% gained
≥3 kg and 11% gained ≥4 kg. Not surprisingly, these
percentages were higher among subgroups with greater
IDWGs. However, these weight gain estimates are con-
servative. The weight gain calculation cohort excluded
patients who did not have 13 contiguous outpatient
treatments in the studied period. Furthermore, we cal-
culated weight gain over a single month. Such weight
gains would snowball over time. These results indicate
that fluid-related weight gain could be a potential un-
intended consequence of UF rate threshold
implementation.
Our findings also underscore the importance of de-
veloping effective IDWG reduction programs. Strict
dietary salt reduction has been demonstrated to lower
IDWG and blood pressure [21, 22]. Dialysis facilities
incorporate salt and fluid restriction counseling into
their dietary education programs. However, patients
report difficulty adhering to these restrictions [10], and
IDWGs remain high [18]. Patient-acceptable, evidence-
based education programs are needed. Beyond curbing
dietary sodium intake, aligning the dialysate sodium
with the serum sodium to avoid sodium-loading pa-
tients may be a viable approach to IDWG reduction
[23]. However, close attention must be paid to poten-
tial hemodynamic consequences [24, 25]. Furthermore,
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Fig. 3 Illustration of fluid-related weight gain calculation for a single representative patient with varying observed IDWGs and UF rates over 12
consecutive treatments.The light gray circles and corresponding dashed lines represent the prescribed UF rates on the basis of observed IDWGs
and prescribed TTs without application of a UF rate threshold across the study month. The horizontal dashed reference line represents a UF rate
of 13 ml/h/kg. For treatments with prescribed UF rates ≥13 mL/h/kg, the black bars represent the calculated amount of fluid-related weight that
would be gained if a UF rate threshold of 13 mL/h/kg was applied. For treatments with prescribed UF rates <13 mL/h/kg, the gray bars represent
the calculated amount of fluid-related weight that would be lost (from prior fluid-related weight gains) if the UF rate was allowed to rise to a level
of 13 mL/h/kg. Detailed methods and an example of the 1-month cumulative fluid-related weight gain computation are provided in Additional
file 1: Table S2. Abbreviations: IDWG, interdialytic weight gain; TT, treatment time; UF, ultrafiltration
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our results emphasize the importance of revisiting the
acceptance of shorter dialysis TTs by U.S. nephrolo-
gists. Several observational studies have suggested
greater mortality risk from shorter TTs [20, 26, 27].
Experience from Australia and New Zealand, and other
countries, demonstrates that longer TTs can be
achieved under the in-center, thrice-weekly treatment
paradigm [28]. In our opinion, implementation of lon-
ger TTs for appropriate patients is feasible in the
current U.S. dialysis delivery system. Modest clinic op-
erations modifications, staff education and improved
patient counseling that begins well in advance of dialy-
sis initiation may facilitate acceptance and implemen-
tation of longer TTs.
Most importantly, our findings highlight the critical
importance of identifying and validating objective mea-
sures of volume status. Such tools will facilitate accurate
estimation and prescription of target weight. Physical
examination findings such as hypertension and edema
have proven to be unreliable volume surrogates [29, 30].
Volume assessment tools such as bioimpedance, blood
volume monitors and lung ultrasound lack validated
clinical protocols and are not widely used. Once volume
assessment tools are validated and incorporated into
practice, target weight achievement will serve as an
excellent measure of facility-level fluid management
practices and an appropriate counter-balance for UF rate
limitations. In our opinion, accurate volume assessment
is a critical unmet need in dialysis care.
A target weight quality measure may help minimize
untoward effects of UF rate reduction by prompting pro-
viders to: 1) focus on extracellular volume status, 2)
more frequently re-assess target weight, 3) emphasize
IDWG minimization and 4) administer extra or longer
treatments when greater IDWGs occur. Thus, despite its
limitations, the proposed target weight measure may
provide an important check and balance for the UF rate
measure. Measure detractors were concerned that the
measure might be too easy to manipulate [7, 31]. For ex-
ample, providers could adjust prescribed target weights
rather than altering care to promote original target
weight achievement. Consideration of the target weight
measure as a QIP reporting measure might reduce this
risk while also providing a means to track UF rate meas-
ure safety concerns. Second, future advances in trans-
mission of clinical data to CMS might allow more
granular, real-time tracking of clinical activity that would
limit opportunities for gaming. Third advances in object-
ive volume status measurement tools will likely facilitate
incorporation of an extracellular volume measure into
Table 6 Calculated patient-level fluid-related weight gains after institution of an UF rate threshold of 13 mL/h/kg (February 2012)a
30-Day Cumulative Difference in
Post-dialysis Weight (kg)
30-Day Cumulative % Difference in
Post-dialysis Weight (%)
Group Mean ± SD Median [Q1, Q3] Mean ± SD Median [Q1, Q3]
Overall 1.4 ± 3.0 0.1 [0.0, 1.2] 2.2 ± 5.0 0.2 [0.0, 1.7]
Females 1.4 ± 3.0 0.1 [0.0, 1.3] 2.5 ± 5.5 0.3 [0.0, 2.0]
Males 1.3 ± 2.9 0.1 [0.0, 1.1] 2.0 ± 4.5 0.2 [0.0, 1.6]
Black race 1.1 ± 2.5 0.0 [0.0, 0.9] 1.7 ± 3.9 0.1 [0.0, 1.4]
Non-black race 1.5 ± 3.2 0.1 [0.0, 1.3] 2.5 ± 5.4 0.3 [0.0, 2.0]
Hispanic ethnicity 1.8 ± 3.3 0.3 [0.0, 1.8] 2.9 ± 5.7 0.5 [0.0, 2.7]
Non-Hispanic ethnicity 1.3 ± 2.9 0.1 [0.0, 1.0] 2.0 ± 4.7 0.2 [0.0, 1.6]
No Heart Failure 1.3 ± 2.8 0.1 [0.0, 1.1] 2.0 ± 4.7 0.2 [0.0, 1.6]
Heart Failure 1.6 ± 3.3 0.1 [0.0, 1.4] 2.5 ± 5.4 0.3 [0.0, 2.0]
TT < 240 Minutes 1.6 ± 3.2 0.2 [0.0, 1.5] 2.6 ± 5.4 0.4 [0.0, 2.2]
TT ≥ 240 Minutes 0.8 ± 2.0 0.0 [0.0, 0.6] 1.1 ± 3.0 0.0 [0.0, 0.9]
IDWG <2 kg 0.4 ± 1.3 0.0 [0.0, 0.2] 0.8 ± 2.5 0.0 [0.0, 0.5]
IDWG ≥2 kg 1.8 ± 3.4 0.4 [0.0, 1.8] 2.8 ± 5.6 0.6 [0.0, 2.5]
IDWG <3 kg 0.7 ± 1.9 0.0 [0.0, 0.5] 1.3 ± 3.5 0.0 [0.0, 1.0]
IDWG ≥3 kg 2.4 ± 3.9 0.7 [0.0, 2.8] 3.6 ± 6.4 0.9 [0.0, 3.7]
IDWG <4 kg 1.0 ± 2.4 0.0 [0.0, 0.8] 1.7 ± 4.3 0.0 [0.0, 1.3]
IDWG ≥4 kg 3.1 ± 4.5 1.2 [0.2, 3.9] 4.4 ± 7.1 1.4 [0.3, 5.1]
UF rate < 13 mL/h/kg 0.5 ± 1.4 0.0 [0.0, 0.4] 0.8 ± 2.2 0.0 [0.0, 0.7]
UF rate ≥ 13 mL/h/kg 4.1 ± 4.6 2.3 [0.8, 6.0] 6.6 ± 7.9 3.4 [1.1, 9.5]
aEstimation of fluid-related weight gains were based on the February 2012 fluid-related weight gain calculation cohort (N = 59,953)
Abbreviations: IDWG Interdialytic weight gain, TT Treatment time, UF Ultrafiltration
Flythe et al. BMC Nephrology  (2017) 18:185 Page 10 of 13
Table 7 Percentage of facility patients with 30-day cumulative fluid-related weight gains above varied thresholds after institution of
an UF rate threshold of 13 mL/h/kg overall and by subgroup (February 2012)a
Group % of facility patients with a 30-day cumulative fluid-related weight gain
≥ + 2 kg ≥ + 3 kg ≥ + 4 kg
Overall 17.4 ± 10.8;
16.0 [9.5, 24.1]
13.3 ± 9.6;
11.6 [6.5, 18.8]
10.6 ± 8.5;
9.1 [4.4, 15.6]
Sex
Female 18.6 ± 14.7;
16.7 [7.9, 27.3]
14.5 ± 13.4;
12.5 [3.3, 22.2]
11.5 ± 11.8;
9.5 [0.0, 18.2]
Male 16.5 ± 12.9;
14.3 [7.1, 24.0]
12.5 ± 11.5;
10.8 [3.4, 19.0]
9.9 ± 10.3;
7.7 [0.0, 15.4]
Race
Black 15.1 ± 18.4;
11.1 [0.0, 22.5]
11.1 ± 16.5;
6.3 [0.0, 16.7]
8.7 ± 14.9;
3.2 [0.0, 12.5]
Non-black 19.4 ± 15.3;
17.1 [9.1, 27.3]
15.2 ± 13.8;
13.0 [5.3, 22.2]
12.2 ± 12.4;
10.0 [1.9, 18.2]
Ethnicity
Hispanic 24.6 ± 28.7;
17.2 [0.0, 34.7]
19.8 ± 26.5;
11.6 [0.0, 28.6]
16.2 ± 24.4;
6.7 [0.0, 23.1]
Non-Hispanic 16.6 ± 11.2;
15.2 [8.8, 23.1]
12.5 ± 10.0;
10.7 [5.6, 18.2]
9.9 ± 9.0;
8.0 [3.4, 14.7]
Heart Failure
(−) Heart failure 16.5 ± 11.9;
15.4 [7.7, 23.5]
12.5 ± 10.6;
10.7 [5.0, 18.2]
9.8 ± 9.6;
8.0 [1.8, 14.5]
(+) Heart failure 20.3 ± 20.3;
16.7 [0.0, 31.0]
15.9 ± 18.7;
11.1 [0.0, 25.0]
12.9 ± 17.1;
7.7 [0.0, 20.0]
Prescribed TT
< 240 min 19.6 ± 12.8;
18.8 [10.3, 27.8]
15.1 ± 11.4;
13.3 [7.1, 22.1]
12.2 ± 10.2;
11.1 [4.5, 18.2]
≥ 240 min 10.7 ± 15.6;
5.7 [0.0, 16.7]
7.3 ± 13.3;
0.0 [0.0, 11.1]
5.2 ± 11.4;
0.0 [0.0, 6.7]
IDWG
< 2 kg 6.0 ± 10.6;
0.0 [0.0, 10.0]
3.9 ± 8.3;
0.0 [0.0, 5.7]
2.8 ± 6.9;
0.0 [0.0, 0.0]
≥ 2 kg 22.3 ± 13.9;
21.1 [12.5, 30.8]
17.3 ± 12.6;
15.4 [8.3, 25.0]
13.8 ± 11.2;
12.0 [5.6, 20.0]
< 3 kg 10.1 ± 9.8;
8.1 [2.4, 15.0]
7.2 ± 8.1;
5.3 [0.0, 11.1]
5.5 ± 7.2;
3.4 [0.0, 8.3]
≥ 3 kg 28.7 ± 19.5;
26.9 [15.4, 40.0]
22.6 ± 18.2;
20.0 [10.0, 33.3]
18.3 ± 16.5;
16.7 [6.3, 26.9]
< 4 kg 13.5 ± 10.0;
12.0 [6.3, 19.0]
10.1 ± 8.7;
8.3 [3.7, 14.3]
7.9 ± 7.6;
6.3 [0.0, 11.8]
≥ 4 kg 36.7 ± 28.1;
33.3 [16.7, 50.0]
29.0 ± 27.0;
25.0 [0.0, 44.4]
23.8 ± 25.5;
20.0 [0.0, 35.7]
Prescribed UF rate
< 13 mL/h/kg 7.3 ± 6.8;
6.3 [2.1, 10.5]
4.7 ± 5.6;
3.6 [0.0, 7.1]
3.3 ± 4.9;
0.0 [0.0, 5.1]
≥ 13 mL/h/kg 53.4 ± 26.7;
50.0 [35.7, 68.8]
43.8 ± 27.2;
42.9 [25.0, 59.4]
36.3 ± 26.7;
33.3 [18.2, 50.0]
aEstimation of weight gains were based on the February 2012 fluid-related weight gain calculation cohort (patient N = 59,953 and facility N = 1752). Values
presented as means ± SDs; medians [quartile 1, quartile 3]
Abbreviations: IDWG Interdialytic weight gain, TT Treatment time, UF Ultrafiltration
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the QIP. In the meantime, the standardized
hospitalization and readmission ratios may provide some
protection against UF rate measure harms but are im-
perfect surrogates [32]. Practitioners must use clinical
judgement when applying UF rate limitations, weighing
the risks of overly rapid fluid removal with the risks of
volume expansion on an individual patient-to-patient
basis.
Strengths of our study include the large, nationally
representative cohort with detailed clinical data and
real-world application of proposed clinical quality meas-
ure criteria. Our study has limitations. First, we consid-
ered data from a single dialysis provider. Clinical
protocols may differ across organizations, raising the
possibility that individual and facility target weight pat-
terns may vary across organizations. Related, target
weights were prescribed by treating nephrologists, and
we lacked data on how target weights were estimated
and prescribed. Clinical approach to target weight esti-
mation likely varied across providers. Second, we esti-
mated the theoretical amount of fluid-related weight
gain that would occur if a prescribed UF rate threshold
of 13 mL/h/kg were implemented. In these calculations,
we used observed IDWGs and prescribed TTs and as-
sumed that these parameters would remain unchanged
after UF rate threshold application. We were unable to
account for possible IDWG reduction or TT extension
that might occur in response to UF rate threshold imple-
mentation in a real-world clinical environment. Third,
we lacked data on residual kidney function and anti-
hypertensive medication use. Finally, we used target
weight and UF rate definitions and selection criteria
according to KCQA specifications, and results cannot be
generalized to excluded patients or facilities.
Conclusions
In conclusion, our data highlight the importance of
reconsidering the target weight measure or developing a
new measure that could serve as a counter-balance to
the UF rate clinical performance measure. As we strive
to protect patients from the consequences of overly ag-
gressive fluid removal, we must apply equal vigilance to
protecting them from the harms of under aggressive
fluid removal. Pilot studies of the proposed fluid-related
quality measures are needed.
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